Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection

NCT02486484 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Neovascularization
Macular Degeneration
Diabetic Retinopathy
Retinal Vein Occlusion
Choroidal Neovascularization
Retinal Neovascularization
Recurrent Pterygium
Cystoid Macular Edema

Interventions

DRUG: ziv-aflibercept

Sponsor

Rafic Hariri University Hospital